TSUTOMU NAGATA JAPAN,MASAHIRO INOUE JAPAN,YUKA ASHIDA JAPAN,KENGO NOGUCHI JAPAN,MAKOTO ONO JAPAN
申请号：
IN1852/MUMNP/2012
公开号：
IN2012MN01852A
申请日:
2012.07.27
申请国别(地区):
IN
年份:
2014
代理人:
摘要：
Compounds represented by general formula (I) (wherein A represents a C3-12 cycloalkyl group optionally substituted by 1-3 substituents selected from among fluoro groups hydroxide groups and/or a C1-6 alkyl groups R1 R2 and R3 each individually represents a hydrogen atom a fluoro group or a C1-6 alkyl group R4 represents a hydrogen atom or a prodrug groupand Y represents -CH2-CHR5-CH2-NHR6 in which R5 represents a hydrogen atom a C1-6 alkyl group or a C1-6 alkoxy group and R6 represents a hydrogen atom or a prodrug group) and pharmacologically-acceptable salts thereof exhibit a TAFIa-inhibiting activity and thus are useful as therapeutic drugs for myocardial infarction angina acute coronary syndrome cerebral infarction deep vein thrombosis pulmonary embolism etc.
